Scoparone as a therapeutic drug in liver diseases : Pharmacology, pharmacokinetics and molecular mechanisms of action
Copyright © 2020 Elsevier Ltd. All rights reserved..
Scoparone is an active and efficious ingredient of herbal medicine Artemisia capillaris Thunb, which has been used clinically in traditional Chinese medicine formula (e.g. Yin-Chen-Hao decoction) for the treatment of hepatic dysfunction, cholestasis and jaundice for over thousand years. More recently, scoparone has received increasing attention due to its multiple properties. In this comprehensive review, we provide the first summary of the pharmacological effects and pharmacokinetic characteristics of scoparone, and discuss future research prospects. The results implicated that scoparone possesses a wide spectrum of pharmacological activities, including anti-inflammatory, antioxidant, anti-apoptotic, anti-fibrotic and hypolipidemic properties. Pharmacokinetic studies have addressed that isoscopoletin and scopoletin are major primary metabolites of scoparone. Moreover, hepatic dysfunction might promote bioavailability of scoparone due to limited intrinsic clearance. On the other hand, the bioavailability of multi-component including scoparone in certain TCM formula can also be enhanced by applying this formula at a high dose on account of their interacted effects. In view of good pharmacological actions, scoparone is anticipated to be a potential drug candidate for various liver diseases, such as acute liver injury, fulminant hepatitis, alcohol-induced hepatotoxicity, non-alcoholic fatty liver disease and fibrosis. However, further studies are warranted to clarify its molecular mechanisms and targets, elucidate its toxicity, and identify its interplay with other active ingredients of classical TCM formula in clinical settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:160 |
|---|---|
| Enthalten in: |
Pharmacological research - 160(2020) vom: 01. Okt., Seite 105170 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hui, Yangyang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coumarins |
|---|
| Anmerkungen: |
Date Completed 13.08.2021 Date Revised 13.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phrs.2020.105170 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314506365 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314506365 | ||
| 003 | DE-627 | ||
| 005 | 20231225152858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2020.105170 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314506365 | ||
| 035 | |a (NLM)32877694 | ||
| 035 | |a (PII)S1043-6618(20)31478-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hui, Yangyang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Scoparone as a therapeutic drug in liver diseases |b Pharmacology, pharmacokinetics and molecular mechanisms of action |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.08.2021 | ||
| 500 | |a Date Revised 13.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Scoparone is an active and efficious ingredient of herbal medicine Artemisia capillaris Thunb, which has been used clinically in traditional Chinese medicine formula (e.g. Yin-Chen-Hao decoction) for the treatment of hepatic dysfunction, cholestasis and jaundice for over thousand years. More recently, scoparone has received increasing attention due to its multiple properties. In this comprehensive review, we provide the first summary of the pharmacological effects and pharmacokinetic characteristics of scoparone, and discuss future research prospects. The results implicated that scoparone possesses a wide spectrum of pharmacological activities, including anti-inflammatory, antioxidant, anti-apoptotic, anti-fibrotic and hypolipidemic properties. Pharmacokinetic studies have addressed that isoscopoletin and scopoletin are major primary metabolites of scoparone. Moreover, hepatic dysfunction might promote bioavailability of scoparone due to limited intrinsic clearance. On the other hand, the bioavailability of multi-component including scoparone in certain TCM formula can also be enhanced by applying this formula at a high dose on account of their interacted effects. In view of good pharmacological actions, scoparone is anticipated to be a potential drug candidate for various liver diseases, such as acute liver injury, fulminant hepatitis, alcohol-induced hepatotoxicity, non-alcoholic fatty liver disease and fibrosis. However, further studies are warranted to clarify its molecular mechanisms and targets, elucidate its toxicity, and identify its interplay with other active ingredients of classical TCM formula in clinical settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Lipid metabolism | |
| 650 | 4 | |a Non-alcoholic fatty liver disease | |
| 650 | 4 | |a Scoparone | |
| 650 | 4 | |a Traditional Chinese medicine | |
| 650 | 7 | |a Coumarins |2 NLM | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 650 | 7 | |a scoparone |2 NLM | |
| 650 | 7 | |a H5841PDT4Y |2 NLM | |
| 700 | 1 | |a Wang, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Zihan |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xiaofei |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Binxin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Tianming |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Lihong |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Hongjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Qingxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bangmao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Xingliang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Chao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 160(2020) vom: 01. Okt., Seite 105170 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:160 |g year:2020 |g day:01 |g month:10 |g pages:105170 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2020.105170 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 160 |j 2020 |b 01 |c 10 |h 105170 | ||